Skip to main content

Coloplast A/S – Announcement no. 02/2021 – Share Buyback Programme

Written by Customer Service on . Posted in Public Companies.

Coloplast A/S (“Coloplast” or the “Company”) is initiating a share buyback programme totalling up to DKK 500 million, as announced in the Company Announcement no. 01/2021 of 2 February 2021. The programme will commence on 22 February 2021 and is expected to end by 23 August 2021.  The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.The programme will commence on 22 February 2021 and is expected to end by 23 August 2021. The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million.The maximum number of shares to be purchased in the Company per daily market session will be the equivalent to 25% of the average volume of shares in the Company traded on Nasdaq Copenhagen A/S during the preceding 20 trading days.During the life of the share buyback programme no shares will be purchased at a price exceeding the higher of the following two prices:i) the price of the last independent trade on Nasdaq Copenhagen A/S and
ii) the highest current independent bid on Nasdaq Copenhagen A/S.Details of transactions executed under the share buyback programme will be disclosed to the market in accordance with the Safe Harbour Regulation and will be publicly disclosed on the company’s website at least once every seventh trading day.Prior to the launch of the share buyback programme Coloplast A/S holds 3,038,288 treasury shares, equal to 1.41% of the company’s share capital.
For further information, please contactInvestors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: dkebj@coloplast.comPress and media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.comAddress
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-02.All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.Attachment02_2021_Share_Buyback_Programme

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.